Key result
The Japan Atherosclerosis Society 2017 guidelines recommend comprehensive risk assessment using the Suita score and strict LDL-C management, including new agents like PCSK9 inhibitors, for preventing atherosclerotic cardiovascular diseases.
This review summarizes the 2017 Japan Atherosclerosis Society guidelines, highlighting the use of the Suita score for risk stratification and the introduction of non-HDL-C targets and newer lipid-lowering therapies.
Answers are grounded in this paper and cite their sources.
May inform Japanese ASCVD prevention; leaves open prospective validation of Suita score and PCSK9 guidance.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Shizuya Yamashita (2018) conducted a review in Atherosclerotic Cardiovascular Diseases and Dyslipidemia. Lipid-lowering therapy was evaluated. The Japan Atherosclerosis Society 2017 guidelines recommend comprehensive risk assessment using the Suita score and strict LDL-C management, including new agents like PCSK9 inhibitors, for preventing atherosclerotic cardiovascular diseases.
Synapse has enriched 10 related papers. Consider them for comparative context: